Eli Lilly and Company Foundation To Fund World-Class Diabetes Treatment and Care Program at Riley Hospital for Children
13th Nov 2006, 22:28 GMT
The Riley Children's Foundation has received a $10 mln gift from the Eli Lilly and Company Foundation that will serve as a transformational catalyst needed to establish a world-class pediatric diabetes treatment and care program at Riley Hospital for Children.
Eli Lilly and Company Foundation To Fund World-Class Diabetes Treatment and Care Program at Riley Hospital for Children related news:
- Eli Lilly and Company Foundation To Fund World-Class Diabetes Treatment and Care Program at Riley Hospital for Children — PR Newswire: All Releases
- Lilly: Arxxant cuts sight loss in diabetes — United Press International - Health Business
- On World Diabetes Day, American Diabetes Assoc Advocates for Greater Health Care Access and Affordability — Nephrology/ Dialysis News from StratCenter.com
- Experts Call for Speedier Heart Care — WebMD Health Headlines
- World Diabetes Day - Raising Voices of People Living With the Disease — AllAfrica News: Zambia
- Zambia: World Diabetes Day - Raising Voices of People Living With the Disease — AllAfrica News: Health and Medicine
- IIF Aims to Draw Attention to Plight of People With Insulin-Requiring Diabetes on World Diabetes Day 2006 — PR Leap - Recent News Releases
- Boy’s death at China hospital spurs riot over care and fees. — Environmental Health News
- Lilly drug reduces blindness in diabetic patients — Pharmaceutical Business Review Latest News
- Diabetes treatment, $1bn a year — AME Info News - Healthcare
Latest news from Operations-Related News from StratCenter.com:
- Senior Housing Properties Trust Announces Proposed Public Offering of 5 mln Common Shares
- King Not Loving Its Shareholders
- Sepracor says asthma drug data is favorable
- Sepracor Presents Data on Asthma Drug
- Dr Reddy's Registers to List Shares
- PolyMedica Corp CEO to Ring the NASDAQ Stock Market Opening Bell
- Biovail to Present at the CSFB 2006 Healthcare Conference
- Genelabs reports lower Q3 loss
- Solexa posts narrowed Q3 loss
- Abbott's Humira Positive in 2 Studies